Back to today’s briefing

Story perspectives

FDA Approves Gene Therapies for Eye Diseases Breakthrough

7/17/2025

32 4

Summary

Story summary

AAVantgarde Bio's groundbreaking AAVB-039 gene therapy has gained FDA approval for clinical trials, offering hope to Stargardt disease patients by targeting the restoration of the crucial ABCA4 protein. In a parallel breakthrough, Nanoscope Therapeutics has submitted a BLA for MCO-010, a revolutionary gene-agnostic treatment for retinitis pigmentosa, showcasing encouraging results from its trials.

1 of 1

Story summary

AAVantgarde Bio's groundbreaking AAVB-039 gene therapy has gained FDA approval for clinical trials, offering hope to Stargardt disease patients by targeting the restoration of the crucial ABCA4 protein. In a parallel breakthrough, Nanoscope Therapeutics has submitted a BLA for MCO-010, a revolutionary gene-agnostic treatment for retinitis pigmentosa, showcasing encouraging results from its trials.